tirzepatide kidney disease 𧬠New data from the SUMMIT trial reveals that long-term (Zepbound) may significantly improve function in patients with obesity, chronic kidney (CKD), and heart failure with preserved ejection fraction ( Cardiorenal benefits of tirzepatide. By
Description
P values were corrected for multiple testing using the BH method (adjusting for the number of tested genes)
If you are satisfied with 3.33 mg/mL, stick with 3.33 mg/mL for every vial
Serious risks are rare
Are you investing in the most advanced medical science available, or in a methodology that has been questioned by the broader medical community
It pushes the boundaries of what we thought was possible
Authors: Patricia J
